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Life-threatening and terminal illnesses are accompanied by 
substantial stressors that encumber both patients and their fami-
lies. Faced with a life-threatening diagnosis such as late-stage 
cancer, these factors can compound the existential crisis of 
impending mortality and produce or exacerbate major depres-
sive and anxiety symptoms (Silverstone, 1990; Vergo et al., 
2016). Addressing depression and anxiety in the unique context 
of life-threatening illnesses has been a significant problem for 
palliative psychiatric care. In this regard, two recent studies 
suggest that the one-time use of the naturally derived psychoac-
tive compound psilocybin could have the potential to alleviate 
these symptoms for up to six months.
Two independent studies by Griffiths et al. (2016) and Ross 
et al. (2016) demonstrate that psilocybin, a serotoninergic psy-
chedelic, can produce a rapid and clinically significant decrease 
in the symptoms of depression and anxiety, which can persist for 
up to six months. Each study utilized a double-blind design and 
employed different active control compounds to address design-
based confounds associated with the use of a psychoactive drug. 
Griffiths et al. (2016) used a low dose (1–3 mg) of psilocybin, 
while Ross et al. (2016) selected niacin. It is worth noting that the 
placebo effect is a major confound in the development of novel 
antidepressant drugs, as placebos can produce antidepressant 
effects in 30–40% of individuals (Papakostas et al., 2016). 
Psilocybin treatment was associated with statistically significant 
antidepressant and anxiolytic effects in both studies. The use of 
two separate control compounds (including a subclinical dose of 
psilocybin as control) minimizes the potential outcome that the 
effects are due to placebo rather than an active drug effect.
Additionally, these studies utilized a crossover design, where 
patients receiving placebo for the first administration were given 
psilocybin in the second half of the study. When patients in this 
latter group were given psilocybin, they also exhibited marked 
reductions in depression and anxiety-related symptoms beyond 
that which may have occurred following administration of the 
control compounds. Together with their larger sample of partici-
pants compared with prior trials (51 and 29, respectively), these 
studies provide support for definitive trials designed to test the 
hypothesis that psilocybin may have therapeutic effects with 
what appear to be minimal side-effects.
A prior open-label study also showed apparent efficacy of 
psilocybin in treatment-resistant depression (Carhart-Harris 
et al., 2016), and although other studies have suggested a role for 
psychedelics such as psilocybin and lysergic acid diethylamide 
(LSD) as adjuncts to psychotherapy (Carhart-Harris et al., 2012; 
Gasser et al., 2014; Grob et al., 2011), these prior studies have 
been criticized for their small sample size and open-label design. 
The current studies represents a significant advance over these 
prior studies by virtue of larger sample sizes and the use of com-
parator compounds as controls.
Serotonin selective reuptake inhibitors (SSRIs) and other 
antidepressants are thought to exert many of their actions, in part, 
by augmenting the concentration of serotonin at the neuronal 
synapse. Indeed, direct activation of serotoninergic nuclei in the 
dorsal raphe can produce antidepressant-like effects in animal 
models (Urban et al., 2016). The antidepressant effects of SSRIs 
and other conventional tricyclic antidepressants, however, 
require at least three to six weeks to achieve clinical efficacy 
(Frazer and Benmansour, 2002), which may not be optimal for 
individuals with terminal illness.
Although SSRIs and psilocybin presumably both work via 
modulating central nervous serotonin, psilocin, the active 
hydroxy metabolite of psilocybin, directly activates serotonin 
receptors, including 5-HT2A receptors located on prefrontal cor-
tical neurons (Willins et al., 1997). Elevated cortical 5-HT2A 
receptor expression has been implicated in depression-related 
suicide (Pandey, 2013; Pandey et al., 2002), and SSRIs have been 
reported to reduce cortical 5-HT2A receptor expression 
(Yamauchi et al., 2006) via a process termed receptor downregu-
lation. Considering that both 5-HT2A antagonists and agonists 
have been found to induce 5-HT2A downregulation (Yadav et al., 
2011), and that several newer generation antidepressants such as 
mirtazepine (Nutt, 1998) possess 5-HT2A antagonist activity, it 
is conceivable that psilocin may possess such sustained antide-
pressant effects with one-time use via downregulating serotonin 
receptors, although further studies are needed to test this hypoth-
esis directly. It should be noted, though, that psilocin has actions 
at essentially all other serotonin receptors (http://kidbdev.med.
unc.edu/databases/kidb.php), and its actions could be due to a 
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combination of actions at many serotonin receptors in addition to 
its agonist actions at 5-HT2A receptors.
Over the past 50 years, the use of psychedelic drugs such as 
psilocybin and LSD as potential therapeutics has remained contro-
versial (Nichols, 2016). The Griffiths et al. (2016) and Ross et al. 
(2016) studies, as well as previous studies (Griffiths et al., 2006), 
suggest that the mystical experience stemming from psilocybin 
sessions may be an integral part of the antidepressant process. 
Given the complex pharmacology of these compounds, however, it 
would be essential to extend these findings, for instance by 
attempting to abrogate the hallucinatory actions via pretreatment 
with a 5-HT2A-selective antagonist. Alternatively, more selective 
5-HT2A agonists exist (e.g., 2,5-dimethoxy-4-iodoamphetamine),
and it would be interesting to see if they have similar apparent
antidepressant actions. This is particularly relevant given the recent 
finding that the antidepressant actions of ketamine may be due to
metabolites, which lack the NMDA-like pharmacology associated
with the parent compound (Zanos et al., 2016).
Nonetheless, the findings of Griffiths et al. (2016) and Ross 
et al. (2016)—that one-time use of psilocybin can produce 
clinically relevant and apparently long-lasting effects on 
depressive and anxious symptoms—are remarkable, and they 
underscore the potential for psilocybin as an alternative to 
first-line antidepressants.
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